Latest Breaking News On - Theragnostics ltd - Page 1 : comparemela.com

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Berlin, Germany, 4 April 2024 - Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it will be presenting a poster, demonstrating its new findings on the discovery of novel macrocyclic.

San diegoUnited statesUnited kingdomMarie curiePureos bioventuresAnika jaekelCancer researchAmerican association for cancer researchTheragnostics ltdLife sciencesAmerican associationAnnual meetingChief executive officerAriceum therapeuticsSenior directorTranslational biology

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

/PRNewswire/ Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain.

United statesUnited kingdomSan diegoAnika jaekelMarie curiePureos bioventuresCancer researchLife sciencesAmerican association for cancer researchTheragnostics ltdAmerican associationAnnual meetingChief executive officerAriceum therapeuticsSenior directorTranslational biology

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMarie curiePureos bioventuresAustin smithPaul mulhollandLife sciencesTheragnostics ltdRegulatory agencyClinical trial authorisationChief executive officerAriceum therapeuticsMedical oncologistMarie curieMerkel cell carcinomaAndera partners

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesMarie curiePureos bioventuresLife sciencesTheragnostics ltdRegulatory agencyUnited kingdom basedChief executive officerAriceum therapeuticsBiotech showcaseMarie curieMerkel cell carcinomaAndera partnersEarlybird venture

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

United kingdomSan franciscoUnited statesCharlotte hepburne scottStephen adamsHelena batesRegulatory agencyTheragnostics ltdStrategic communicationsUnited kingdom basedChief executive officerAriceum therapeuticsBiotech showcaseZoe bolt